Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Yasuto Takeuchi, Fusao Ikeda, Toshiya Osawa, Yasuyuki Araki, Kouichi Takaguchi, Youichi Morimoto, Noriaki Hashimoto, Kousaku Sakaguchi, Tatsuro Sakata, Masaharu Ando, Yasuhiro Makino, Shuji Matsumura, Hiroki Takayama, Hiroyuki Seki, Shintarou Nanba, Yuki Moritou, Tetsuya Yasunaka, Hideki Ohnishi, Akinobu Takaki, Kazuhiro Nouso & 2 others Yoshiaki Iwasaki, Kazuhide Yamamoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

AIM: To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5ng/mL before therapy and in non-SVR patients showing AFP ≥ 5ng/mL before and 1year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5ng/mL before therapy and no decrease in AFP to <5ng/mL 1year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5ng/ mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP <5ng/mL before therapy than in those showing AFP ≥ 5ng/mL. CONCLUSION: The criteria of AFP <5ng/mL before and 1year after IFN therapy is a benefical predictor for HCC development in CHC patients.

Original languageEnglish
Pages (from-to)2220-2228
Number of pages9
JournalWorld Journal of Hepatology
Volume7
Issue number19
DOIs
Publication statusPublished - 2015

Fingerprint

alpha-Fetoproteins
Interferons
Hepatocellular Carcinoma
Chronic Hepatitis C
Platelet Count
Therapeutics
Alanine Transaminase
Propensity Score
Ribavirin
Incidence
Proportional Hazards Models
Antiviral Agents
Cohort Studies
Logistic Models
Regression Analysis

Keywords

  • Alpha-fetoprotein
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Interferon

ASJC Scopus subject areas

  • Hepatology

Cite this

Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. / Takeuchi, Yasuto; Ikeda, Fusao; Osawa, Toshiya; Araki, Yasuyuki; Takaguchi, Kouichi; Morimoto, Youichi; Hashimoto, Noriaki; Sakaguchi, Kousaku; Sakata, Tatsuro; Ando, Masaharu; Makino, Yasuhiro; Matsumura, Shuji; Takayama, Hiroki; Seki, Hiroyuki; Nanba, Shintarou; Moritou, Yuki; Yasunaka, Tetsuya; Ohnishi, Hideki; Takaki, Akinobu; Nouso, Kazuhiro; Iwasaki, Yoshiaki; Yamamoto, Kazuhide.

In: World Journal of Hepatology, Vol. 7, No. 19, 2015, p. 2220-2228.

Research output: Contribution to journalArticle

Takeuchi, Y, Ikeda, F, Osawa, T, Araki, Y, Takaguchi, K, Morimoto, Y, Hashimoto, N, Sakaguchi, K, Sakata, T, Ando, M, Makino, Y, Matsumura, S, Takayama, H, Seki, H, Nanba, S, Moritou, Y, Yasunaka, T, Ohnishi, H, Takaki, A, Nouso, K, Iwasaki, Y & Yamamoto, K 2015, 'Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development', World Journal of Hepatology, vol. 7, no. 19, pp. 2220-2228. https://doi.org/10.4254/wjh.v7.i19.2220
Takeuchi, Yasuto ; Ikeda, Fusao ; Osawa, Toshiya ; Araki, Yasuyuki ; Takaguchi, Kouichi ; Morimoto, Youichi ; Hashimoto, Noriaki ; Sakaguchi, Kousaku ; Sakata, Tatsuro ; Ando, Masaharu ; Makino, Yasuhiro ; Matsumura, Shuji ; Takayama, Hiroki ; Seki, Hiroyuki ; Nanba, Shintarou ; Moritou, Yuki ; Yasunaka, Tetsuya ; Ohnishi, Hideki ; Takaki, Akinobu ; Nouso, Kazuhiro ; Iwasaki, Yoshiaki ; Yamamoto, Kazuhide. / Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development. In: World Journal of Hepatology. 2015 ; Vol. 7, No. 19. pp. 2220-2228.
@article{111b17fe91c548779c1d23dbdd81754a,
title = "Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development",
abstract = "AIM: To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5ng/mL before therapy and in non-SVR patients showing AFP ≥ 5ng/mL before and 1year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5ng/mL before therapy and no decrease in AFP to <5ng/mL 1year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5ng/ mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP <5ng/mL before therapy than in those showing AFP ≥ 5ng/mL. CONCLUSION: The criteria of AFP <5ng/mL before and 1year after IFN therapy is a benefical predictor for HCC development in CHC patients.",
keywords = "Alpha-fetoprotein, Hepatitis C virus, Hepatocellular carcinoma, Interferon",
author = "Yasuto Takeuchi and Fusao Ikeda and Toshiya Osawa and Yasuyuki Araki and Kouichi Takaguchi and Youichi Morimoto and Noriaki Hashimoto and Kousaku Sakaguchi and Tatsuro Sakata and Masaharu Ando and Yasuhiro Makino and Shuji Matsumura and Hiroki Takayama and Hiroyuki Seki and Shintarou Nanba and Yuki Moritou and Tetsuya Yasunaka and Hideki Ohnishi and Akinobu Takaki and Kazuhiro Nouso and Yoshiaki Iwasaki and Kazuhide Yamamoto",
year = "2015",
doi = "10.4254/wjh.v7.i19.2220",
language = "English",
volume = "7",
pages = "2220--2228",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "19",

}

TY - JOUR

T1 - Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

AU - Takeuchi, Yasuto

AU - Ikeda, Fusao

AU - Osawa, Toshiya

AU - Araki, Yasuyuki

AU - Takaguchi, Kouichi

AU - Morimoto, Youichi

AU - Hashimoto, Noriaki

AU - Sakaguchi, Kousaku

AU - Sakata, Tatsuro

AU - Ando, Masaharu

AU - Makino, Yasuhiro

AU - Matsumura, Shuji

AU - Takayama, Hiroki

AU - Seki, Hiroyuki

AU - Nanba, Shintarou

AU - Moritou, Yuki

AU - Yasunaka, Tetsuya

AU - Ohnishi, Hideki

AU - Takaki, Akinobu

AU - Nouso, Kazuhiro

AU - Iwasaki, Yoshiaki

AU - Yamamoto, Kazuhide

PY - 2015

Y1 - 2015

N2 - AIM: To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5ng/mL before therapy and in non-SVR patients showing AFP ≥ 5ng/mL before and 1year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5ng/mL before therapy and no decrease in AFP to <5ng/mL 1year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5ng/ mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP <5ng/mL before therapy than in those showing AFP ≥ 5ng/mL. CONCLUSION: The criteria of AFP <5ng/mL before and 1year after IFN therapy is a benefical predictor for HCC development in CHC patients.

AB - AIM: To investigate factors that accurately predict hepatocellular carcinoma (HCC) development after antiviral therapy in chronic hepatitis C (CHC) patients. METHODS: CHC patients who received pegylated interferon and ribavirin were enrolled in this cohort study that investigated the ability of alpha-fetoprotein (AFP) to predict HCC development after interferon (IFN) therapy. RESULTS: Of 1255 patients enrolled, 665 developed sustained virological response (SVR) during mean follow-up period of 5.4 years. HCC was occurred in 89 patients, and 20 SVR patients were included. Proportional hazard models showed that HCC occurred in SVR patients showing AFP ≥ 5ng/mL before therapy and in non-SVR patients showing AFP ≥ 5ng/mL before and 1year after therapy besides older age, and low platelet counts. SVR patients showing AFP ≥ 5ng/mL before therapy and no decrease in AFP to <5ng/mL 1year after therapy had significantly higher HCC incidence than non-SVR patients showing AFP ≥ 5ng/ mL before therapy and decreased AFP (P = 0.043). AFP ≥ 5ng/mL before therapy was significantly associated with low platelet counts and high values of alanine aminotransferase (ALT) in stepwise logistic regression analysis. After age, gender, platelet count, and ALT was matched by propensity score, significantly lower HCC incidence was shown in SVR patients showing AFP <5ng/mL before therapy than in those showing AFP ≥ 5ng/mL. CONCLUSION: The criteria of AFP <5ng/mL before and 1year after IFN therapy is a benefical predictor for HCC development in CHC patients.

KW - Alpha-fetoprotein

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=84941101457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941101457&partnerID=8YFLogxK

U2 - 10.4254/wjh.v7.i19.2220

DO - 10.4254/wjh.v7.i19.2220

M3 - Article

VL - 7

SP - 2220

EP - 2228

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 19

ER -